IM Cannabis Corp. (IMCC)
USD 1.73
(2.37%)
USD 1.73
(2.37%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 11.96 Million CAD | 31.74% |
| 2022 | 9.08 Million CAD | -40.87% |
| 2021 | 15.36 Million USD | 294.62% |
| 2020 | -7.89 Million CAD | 38.68% |
| 2019 | -12.87 Million CAD | -34698.12% |
| 2018 | -37 Thousand CAD | -819.08% |
| 2017 | -4026.00 CAD | -164.2% |
| 2016 | 6271.00 CAD | 8.66% |
| 2015 | 5771.00 CAD | 879.86% |
| 2014 | -740.00 CAD | -102.59% |
| 2013 | 28.61 Thousand CAD | 41.95% |
| 2012 | 20.16 Thousand CAD | 176.55% |
| 2011 | -26.33 Thousand CAD | 94.43% |
| 2010 | -472.67 Thousand CAD | 77.8% |
| 2009 | -2.12 Million CAD | -250.84% |
| 2008 | -606.77 Thousand CAD | -88.86% |
| 2007 | -321.27 Thousand CAD | 70.02% |
| 2006 | -1.07 Million CAD | -200.05% |
| 2005 | -357.11 Thousand CAD | -45.31% |
| 2004 | -245.76 Thousand CAD | 65.95% |
| 2003 | -721.77 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 15.04 Million CAD | 20.35% |
| 2024 Q1 | 12.49 Million CAD | 4.43% |
| 2023 Q1 | 8.59 Million USD | -5.37% |
| 2023 Q2 | 11.96 Million CAD | 39.13% |
| 2023 Q4 | 11.96 Million CAD | 15.34% |
| 2023 FY | 11.96 Million CAD | 31.74% |
| 2023 Q3 | 10.37 Million CAD | -13.24% |
| 2022 Q2 | 30.16 Million CAD | 23.54% |
| 2022 Q3 | 4.53 Million CAD | -84.97% |
| 2022 Q1 | 24.41 Million CAD | 58.91% |
| 2022 Q4 | 9.08 Million CAD | 100.42% |
| 2022 FY | 9.08 Million CAD | -40.87% |
| 2021 Q2 | -19.1 Million CAD | -275.36% |
| 2021 Q1 | 10.89 Million CAD | 237.97% |
| 2021 Q3 | 7.23 Million CAD | 137.87% |
| 2021 Q4 | 15.36 Million USD | 112.4% |
| 2021 FY | 15.36 Million USD | 294.62% |
| 2020 Q2 | -12.15 Million CAD | -15.05% |
| 2020 Q4 | -7.89 Million CAD | 9.45% |
| 2020 Q3 | -8.71 Million CAD | 28.29% |
| 2020 Q1 | -10.56 Million CAD | 18.93% |
| 2020 FY | -7.89 Million CAD | 38.68% |
| 2019 Q1 | 1.75 Million CAD | 5145.41% |
| 2019 FY | -12.87 Million CAD | -34698.12% |
| 2019 Q2 | 831.88 Thousand CAD | -52.68% |
| 2019 Q3 | -459 Thousand CAD | -155.18% |
| 2019 Q4 | -13.03 Million CAD | -2739.87% |
| 2018 Q1 | -4026.00 CAD | -117.91% |
| 2018 FY | -37 Thousand CAD | -819.08% |
| 2018 Q4 | 33.51 Thousand CAD | 0.0% |
| 2017 Q2 | 6432.00 CAD | 2.57% |
| 2017 Q4 | 22.48 Thousand CAD | 166.15% |
| 2017 Q3 | 8448.00 CAD | 31.34% |
| 2017 Q1 | 6271.00 CAD | 0.0% |
| 2017 FY | -4026.00 CAD | -164.2% |
| 2016 FY | 6271.00 CAD | 8.66% |
| 2015 FY | 5771.00 CAD | 879.86% |
| 2014 Q3 | 76.12 Thousand CAD | 138.87% |
| 2014 FY | -740.00 CAD | -102.59% |
| 2014 Q1 | 28.61 Thousand CAD | 287.67% |
| 2014 Q4 | -11.23 Thousand CAD | -114.76% |
| 2014 Q2 | 31.86 Thousand CAD | 11.36% |
| 2013 FY | 28.61 Thousand CAD | 41.95% |
| 2013 Q4 | 7382.00 CAD | 438.62% |
| 2013 Q3 | -2180.00 CAD | -109.39% |
| 2013 Q2 | 23.21 Thousand CAD | 15.12% |
| 2013 Q1 | 20.16 Thousand CAD | 761.45% |
| 2012 FY | 20.16 Thousand CAD | 176.55% |
| 2012 Q1 | -26.33 Thousand CAD | 85.69% |
| 2012 Q3 | -25.19 Thousand CAD | 88.84% |
| 2012 Q4 | -3048.00 CAD | 87.9% |
| 2012 Q2 | -225.82 Thousand CAD | -757.48% |
| 2011 Q2 | -378.68 Thousand CAD | 19.88% |
| 2011 Q4 | -183.98 Thousand CAD | -40.05% |
| 2011 FY | -26.33 Thousand CAD | 94.43% |
| 2011 Q1 | -472.67 Thousand CAD | -36.97% |
| 2011 Q3 | -131.36 Thousand CAD | 65.31% |
| 2010 Q1 | -2.12 Million CAD | 15.72% |
| 2010 Q2 | -1.47 Million CAD | 30.49% |
| 2010 Q3 | -807.47 Thousand CAD | 45.43% |
| 2010 FY | -472.67 Thousand CAD | 77.8% |
| 2010 Q4 | -345.08 Thousand CAD | 57.26% |
| 2009 Q4 | -2.52 Million CAD | -1821.72% |
| 2009 Q3 | -131.43 Thousand CAD | 60.04% |
| 2009 FY | -2.12 Million CAD | -250.84% |
| 2009 Q2 | -328.92 Thousand CAD | 45.79% |
| 2009 Q1 | -606.77 Thousand CAD | -35.24% |
| 2008 FY | -606.77 Thousand CAD | -88.86% |
| 2008 Q4 | -448.65 Thousand CAD | 53.81% |
| 2008 Q3 | -971.36 Thousand CAD | 50.13% |
| 2008 Q2 | -1.94 Million CAD | -506.23% |
| 2008 Q1 | -321.27 Thousand CAD | 64.74% |
| 2007 Q1 | -1.07 Million CAD | -365.01% |
| 2007 Q3 | -583.18 Thousand CAD | 43.63% |
| 2007 Q2 | -1.03 Million CAD | 3.44% |
| 2007 FY | -321.27 Thousand CAD | 70.02% |
| 2007 Q4 | -911.06 Thousand CAD | -56.22% |
| 2006 Q4 | -230.42 Thousand CAD | 0.11% |
| 2006 FY | -1.07 Million CAD | -200.05% |
| 2006 Q2 | -305.35 Thousand CAD | 14.49% |
| 2006 Q1 | -357.11 Thousand CAD | -1403.32% |
| 2006 Q3 | -230.68 Thousand CAD | 24.45% |
| 2005 Q4 | -23.75 Thousand CAD | 65.19% |
| 2005 FY | -357.11 Thousand CAD | -45.31% |
| 2005 Q1 | -245.76 Thousand CAD | -36.93% |
| 2005 Q3 | -68.24 Thousand CAD | -177.9% |
| 2005 Q2 | -24.55 Thousand CAD | 90.01% |
| 2004 Q3 | -576.32 Thousand CAD | 11.99% |
| 2004 Q4 | -179.47 Thousand CAD | 68.86% |
| 2004 Q1 | -721.77 Thousand CAD | -9.34% |
| 2004 FY | -245.76 Thousand CAD | 65.95% |
| 2004 Q2 | -654.84 Thousand CAD | 9.27% |
| 2003 Q3 | -702 Thousand CAD | -521.03% |
| 2003 Q2 | 166.73 Thousand CAD | 0.0% |
| 2003 FY | -721.77 Thousand CAD | 0.0% |
| 2003 Q4 | -660.11 Thousand CAD | 5.97% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 87.295% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 84.031% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 97.251% |
| Cosmos Health Inc. | 8.59 Million USD | -39.324% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 245.724% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 97.391% |
| Cronos Group Inc. | -663.32 Million USD | 101.804% |
| Incannex Healthcare Limited | -5.48 Million USD | 318.213% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 182.137% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 90.181% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 512.521% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 176.554% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 176.554% |
| SCYNEXIS, Inc. | -19.35 Million USD | 161.855% |
| Safety Shot Inc | -2.28 Million USD | 623.951% |
| Theratechnologies Inc. | 24.87 Million USD | 51.876% |
| Alpha Teknova, Inc. | 1.97 Million USD | -506.332% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -5969.196% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 97.234% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 574.96% |
| Dynavax Technologies Corporation | 106.63 Million USD | 88.776% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 98.08% |
| Radius Health, Inc. | 359.28 Million USD | 96.669% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 226.928% |
| Alvotech | 1.06 Billion USD | 98.875% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 109.149% |
| SIGA Technologies, Inc. | -148.68 Million USD | 108.05% |
| Shineco, Inc. | 29.29 Million USD | 59.137% |
| Silver Spike Investment Corp. | -32.61 Million USD | 136.702% |
| Journey Medical Corporation | -9.7 Million USD | 223.277% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 336.524% |
| Embecta Corp. | 1.31 Billion USD | 99.088% |
| Harrow Health, Inc. | 116.41 Million USD | 89.719% |
| Procaps Group, S.A. | 242.93 Million USD | 95.073% |
| Biofrontera Inc. | 4.05 Million USD | -195.094% |
| DURECT Corporation | -7.65 Million USD | 256.376% |
| PainReform Ltd. | -7.95 Million USD | 250.553% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 135.7% |
| OptiNose, Inc. | 58.06 Million USD | 79.387% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 330.793% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 20.276% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -11100.741% |
| ProPhase Labs, Inc. | 19.23 Million USD | 37.762% |
| Phibro Animal Health Corporation | 454.84 Million USD | 97.369% |
| Procaps Group S.A. | 242.93 Million USD | 95.073% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -225.421% |
| Viatris Inc. | 17.13 Billion USD | 99.93% |
| Rockwell Medical, Inc. | 4.45 Million USD | -168.604% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 345.417% |
| Tilray Brands, Inc. | 158.97 Million USD | 92.471% |
| PetIQ, Inc. | 351.93 Million USD | 96.599% |
| Talphera, Inc. | -5.72 Million USD | 309.212% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 93.249% |
| Alimera Sciences, Inc. | 55.3 Million USD | 78.36% |
| Assertio Holdings, Inc. | -32.52 Million USD | 136.795% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 903.978% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -183.827% |
| Hempacco Co., Inc. | 13.61 Million USD | 12.088% |
| Alvotech | 1.06 Billion USD | 98.875% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 112.376% |
| Kamada Ltd. | -46.43 Million USD | 125.778% |
| Currenc Group, Inc. | -16.57 Million USD | 172.219% |
| Indivior PLC | -33.95 Million USD | 135.253% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -4493.321% |
| Flora Growth Corp. | -713 Thousand USD | 1778.682% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 245.724% |
| Evolus, Inc. | 63.7 Million USD | 81.213% |
| HUTCHMED (China) Limited | -197.45 Million USD | 106.062% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 97.502% |
| Akanda Corp. | 3.9 Million USD | -206.511% |